Estrogens may influence gastric cancer risk but published studies are inconclusive. We therefore performed a meta-analysis addressing the associations of gastric cancer in women with menstrual and reproductive factors, and with use of estrogen-and antiestrogen-related therapies. Searches of PubMed up to June, 2011 and review of citations yielded a total of 28 independent studies including at least one exposure of interest. Random effects pooled estimates of relative risk (RR) and corresponding 95% confidence intervals (CI) were calculated for eight exposures reported in at least five studies, including: age at menarche, age at menopause, years of fertility, parity, age at first birth, oral contraceptive use, hormone replacement therapy (HRT), and tamoxifen treatment. Longer years of fertility (RR= 0.74; 95% CI= 0.63 to 0.86) and HRT (RR= 0.77, 95% CI= 0.64 to 0.92) were each associated with decreased gastric cancer risk. Conversely, tamoxifen treatment was associated with increased risk (RR= 1.82, 95% CI= 1.39 to 2.38). The other five exposures were not significantly associated. Our analysis supports the hypothesis that longer exposure to estrogen effects of either ovarian or exogenous origin may decrease risk of gastric cancer. Additional studies are warranted to extend this finding and to identify the underlying mechanisms.
BACKGROUND
Gastric cancer represents the fourth most common cancer and the second leading cause of cancer death worldwide (1) . Notably, for most populations in both high and low incidence regions, the overall incidence in males is approximately double that of females (2, 3) . Since these sex differences cannot be totally explained by variations in sociodemographic characteristics, environmental factors or Helicobacter pylori (H. pylori) infection (4, 5) , female sex hormones have been proposed to be protective (6) . This hypothesis has been previously evaluated by examining associations of gastric cancer risk in women with sex hormone -related exposures, but most individual studies have been inconclusive. To more precisely characterize the reported associations, we have performed a meta-analysis of these data.
MATERIALS AND METHODS
We searched for studies published in any language before June 30, 2011 evaluating the associations of sex hormone-related exposures with gastric cancer incidence or mortality, using PubMed® software to search Medline (U.S. National Library of Medicine, Bethesda, MD).
To identify studies of menstrual and reproductive factors, as well as exogenous estrogens, the following search strategy was used: (gastric cancer OR stomach cancer OR stomach neoplasms) AND (reproductive factors OR menstrual factors OR age at menarche OR menarche OR menstruation OR parity OR pregnancy OR breastfeeding OR miscarriage OR abortion OR fertility OR age at menopause OR estrogens OR sex hormones OR ovariectomy OR oophorectomy OR hysterectomy OR sex differences OR male predominance OR exogenous hormones OR oral contraceptives OR hormone replacement therapy OR menopausal hormone therapy OR climacteric OR reproductive history) AND (risk assessment OR risk OR risk factors OR epidemiology) AND (case-control studies OR case-control OR cohort studies OR cohort).
Reference lists of the selected papers were also screened for other potential articles that may have been missed in the database search. If necessary, we attempted to contact the authors to request additional information. . We also reviewed the reference lists of identified articles and of two previous meta-analyses addressing the associations of tamoxifen therapy with breast cancer recurrence and with adverse effects (7, 8) .
Two investigators in our team independently reviewed the articles and extracted the data; any disagreement was resolved by consulting a third reviewer. For inclusion in this re-analysis, the studies had to present adjusted estimates of relative risk (or similar measures of association including odds ratios; RR), and corresponding 95% confidence intervals (CIs). If anatomical subsite-specific RRs were reported, we extracted data on noncardia gastric cancer only. While gastric cancer risk was purportedly increased with tamoxifen exposure presumed from date of Pooled risk estimates were calculated for exposure variables that were reported in at least five studies, which included: age at menarche, age at menopause, years of fertility (defined as years between menarche and menopause in all but one study, which also omitted periods of pregnancy (11)), parity, age at first birth, oral contraceptive (OC) use, hormone replacement therapy (HRT), and tamoxifen treatment.
Other sex hormone-related variables reported in fewer than five studies included: menstrual regularity, number of pregnancies, age at first pregnancy, breastfeeding of offspring, spontaneous abortion, induced abortion, oophorectomy, hysterectomy, menopausal status, intrauterine device use, parenteral contraceptive use, tubal sterilization, duration of OC use, duration of HRT, and history of endometriosis or vaginosis.
Exposures to exogenous estrogens and tamoxifen therapy were analyzed as dichotomous variables. Since some studies reported associations for varying durations of OC use as compared to never use, we pooled those risk estimates using random effects meta-analysis to estimate the overall effect for ever versus never use. Because the categories of other exposure measures varied across studies, we performed a meta-analysis of the comparison of the highest versus the lowest category (or the inverse of the comparison of the lowest versus the highest category, as applicable) in each study. For two instances in which an adjusted RR for this comparison was unavailable, we calculated a crude RR (with Fisher exact 95% CI) from the reported data. Based on the 95% CI, we calculated the standard error (se) for the ln(RR) by the formula: se=(ln(upper limit) -ln(lower limit))/(2*Z 1-α/2 ), where for a 95% CI, Z 1-α/2 equal to 1.96 (12) . Pooled RRs with corresponding 95% CI were then obtained using the random effects method of DerSimonian and Laird, with inverse variance weights (13) . Between-study heterogeneity was assessed for statistical significance using the Q statistic and quantified with the I 2 study adjusted for a proxy variable related to socioeconomic status (SES) such as education, income or occupation. Galbraith plots were used to identify studies which were major contributors to heterogeneity (16) . Given that SES is inversely associated with gastric cancer risk (17) and is also an important predictor of HRT use (18), we tried to minimize confounding with an alternative meta-analysis which excluded three studies that did not adjust for any SES-related variables.
Since some studies of tamoxifen reported no gastric cancers in one of the treatment groups, we could not compute individual RR estimates. We therefore summed the gastric cancers and corresponding person-time for tamoxifen treated and untreated groups, separately for randomized trials and observational studies. Summary RRs (with Fisher exact 95% CI) were derived for the two marginal analyses, and then pooled using a random effects meta-analysis.
Publication bias was investigated by visual inspection of Begg's funnel plots and formally tested using Egger's regression asymmetry method (19, 20) . The influence of individual studies on the overall meta-analysis RR was assessed by sequentially dropping each one before pooling studyspecific RRs. A priori, we considered an influential study to be one for which its exclusion altered the overall pooled RR by more than 10%.
Statistical analyses were performed with Stata version 11 (StataCorp, College Station, TX) using a combination of published macros for meta-analysis, including metan, metainf, metareg, galbr and metabias (21) . A p-value ≤ 0.05 was considered statistically significant for all tests except evaluation that also led to identification of five more citations from their collective references ( Figure 1A ). Thus, 24 articles (23 written in English and 1 in Japanese) reported associations of at least one sex hormone-related variable with gastric cancer risk (11, two adjusted RRs could not be pooled with others comparing the highest versus the lowest categories, so we calculated and used crude RRs instead.
Literature search for tamoxifen exposure
The two independent literature searches identified 115 citations that were potentially relevant to this re-analysis ( Figure 1B) . Based on the information provided in the title and abstract, we retrieved for further evaluation 13 articles in which drug therapy in the treatment arm differed from that in the control arm solely by the use of tamoxifen. References of these articles and of two previous meta-analyses led to identification of 12 additional studies. Besides irrelevant and duplicate citations, we excluded articles that had either no cases of gastric cancer or did not distinguish them within larger categories (e.g., digestive tract). There were overlapping results from the Danish Breast Cancer Cooperative Group (45, 46), the Christ Hospital Adjuvant Tamoxifen Trial (47, 48), the B-14 trial (49, 50) , and the Stockholm Breast Cancer Study Group (51, 52) , so data from the more recent articles were extracted (46, 48, 50, 52) . In addition, two reports based on US cancer registrations overlapped (53, 54) , so data from the longer study period were extracted (53) . Thus, a total of 14 independent studies, including nine randomized trials (48, 50, 52, (55) (56) (57) (58) (59) (60) and five cohorts (46, 53, (61) (62) (63) , were included in the meta-analysis (Table 2) .
Years of fertility
For the analysis of years of fertility, a total of eight studies were identified (11, 26, 27, 30, 31, 35, 36, 38; Figure 2A ). Study-specific RRs for the longest versus the shortest duration of fertility ranged from 0.55 to 0.99. The pooled RR suggested a significant inverse association with a 26% decreased risk of gastric cancer (Table 3 ) and low between-study heterogeneity. The pooled RR was robust to the exclusion of any individual study.
Age at menarche
Associations of gastric cancer with age at menarche were reported in 11 studies (11, 26, 27, 29, 30, 35-38, 41, 42) . Study-specific RRs for the oldest age at menarche as compared to the youngest age ranged from 0.70 to 1.93, and the pooled RR was 1.0 (Table 3) . Between-study heterogeneity was high, but meta-regression analysis of potential explanatory factors failed to 
Age at menopause
Ten studies examined the association of gastric cancer and age at menopause (11, 26, 27, 29, 30, 35-38, 41). Study-specific RRs for the oldest age at menopause as compared to the youngest ranged from 0.52 to 1.44. The pooled RR was 0.84 (95% CI= 0.67 to 1.05), with low heterogeneity across studies. This estimate was robust to the exclusion of any individual study.
The pooled RR was 0.81 (95% CI= 0.62 to 1.06) for the eight studies (including data from Risk estimates for oldest versus youngest age at first birth were reported in 10 studies (11, 26, 27, 29, 30, 36-39, 41) and ranged from 0.43 to 1.45. The pooled RR was 0.99 (95% CI= 0.85 to 1.15), with low heterogeneity among the studies (Table 3 ). This estimate was robust to the exclusion of any individual study.
Oral contraceptive use
Risk estimates for ever vs. never OC use were reported in four studies ( The pooled RR derived with exclusion of those studies was 1.11 (95% CI= 0.87 to 1.42). Figure 2B represents a forest plot of the effect size distribution for the seven studies that reported on post-menopausal HRT (11, 32, 35-37, 41, 44). The proportion of HRT users ranged from 4% in China (36) to 55% in the US (41). The pooled RR of gastric cancer for ever users of HRT as compared to never users was 0.77 (95% CI=0.64 to 0.92), and there was low heterogeneity among all studies. The average pooled RR was robust to the exclusion of any one study from the overall meta-analysis. In a sensitivity analysis restricted to the four studies that adjusted for a proxy variable of SES (11, 32, 35, 36), the point pooled RR was minimally changed but statistical significance was lost (RR=0.80; 95% CI= 0.60 to 1.06). Table 2 summarizes studies with data for comparison of primary gastric cancer incidence among women treated or untreated with tamoxifen. Nine randomized controlled trials including 33,329 patients reported a total of 19 gastric cancer cases in the tamoxifen arms and 14 in the control arms. Five separate observational cohort studies reported combined incidence rates of 0.57 and 0.30 gastric cancers per 1,000 patient-years in the tamoxifen-treated and -untreated groups, respectively. Thus, tamoxifen treatment was associated with a non-significantly increased risk in the randomized trials (RR= 1.35; 95% CI= 0.64 to 2.92) and a significantly increased risk in the observational studies (RR= 1.90; 95% CI= 1.41 to 2.52). A meta-analysis of these two marginal RRs (with inverse variance weights of 13% and 87%, respectively) found a significantly increased gastric cancer risk among women treated with tamoxifen (RR= 1.82; 95% CI=1.39 to 2.38).
Hormone replacement therapy

Tamoxifen therapy
Publication bias
The p-values for Egger's test of publication bias were greater than 0.1 for all exposure variables with the exception of OC use (P= 0.10; Table 3 ). Figure 2 presents Begg's funnel plots for years of fertility (2C) and HRT (2D), the two variables found to be significantly associated with gastric cancer risk.
DISCUSSION
Although much has been learned about the epidemiology of gastric cancer, it is still unclear why males have higher risk than females. Our meta-analysis identified decreased gastric cancer risks among women with longer duration of fertility or exposure to HRT, and increased risk with exposure to the antiestrogenic agent tamoxifen. However, we found no significant associations with age at menarche, age at menopause, parity, age at first birth or OC use. On balance, these findings support the notion that estrogen exposure influences the risk of gastric cancer in women.
Given the narrow range of age at menarche, variation of years of fertility is mainly determined by age at menopause. Accordingly, we expected similar associations of gastric cancer with these latter two variables, at least with restriction to the common set of eight studies in which both variables were reported. A potential explanation for the discrepancy in our results, not addressable with aggregated data, may be inconsistency between these variables in categorizing individuals as having high (or low) exposure within a given study.
The other null associations of our analysis may also be understood in context. OC use is not a strong risk factor for breast cancer, an estrogen-driven malignancy (64, 65) . Hence, it may not be surprising that OC use does not appear to be associated with gastric cancer risk, for which estrogen exposure presumably has a smaller role. Furthermore, parity and age at first birth do not have clear interpretations regarding quantitative exposure to estrogen, so the failure to find significant associations with these variables is less relevant to the estrogen hypothesis.
The studies we included vary with respect to the factors controlled in the original analyses.
Although we used the reported multivariable adjusted RRs where available, there may have been residual confounding. In the case of HRT, it is possible that postmenopausal women who used hormone therapy may have differed from never users in ways that influence their risk of gastric cancer. Nevertheless, the four studies that adjusted for these differences with a proxy variable for SES had a similar pooled RR as all seven studies of HRT. Thus, confounding by SES would not explain the association between HRT use and gastric cancer, to the extent that these proxies adequately controlled for SES differences without residual confounding.
As a selective estrogen receptor modulator, tamoxifen has both anti-estrogenic (e.g., breast tissue) and estrogenic (e.g., bone) effects (66). In a mouse model of gastric cancer, tamoxifen upregulated estrogen-responsive pathways and prevented gastric cancer development (67). We found an opposite effect on risk of gastric cancer in humans, which may speculatively reflect species differences in gastric epithelial susceptibility to the dual tamoxifen effects. Additional potential explanations for the inconsistency between animal and epidemiological studies include differences in relative age, dose and duration of treatment as well as drug metabolism.
Chronic infection with H. pylori is the primary cause of gastric cancer, and this bacterium is designated a Class I carcinogen by the World Health Organization (68). Sex differences in age at acquisition and infection prevalence have been proposed as potential explanations for 
differences in gastric cancer incidence between males and females (3, 69, 70) . Indeed, a metaanalysis of international population-based surveys (71) found that males had slightly higher infection prevalence among adults (adjusted OR= 1.16), but not among children. Studies measuring spontaneous clearance of H. pylori infection by sex have varied, with some studies indicating slightly higher seroreversion rates for women than men (72-74) while others found similar rates (75) (76) (77) . Regarding therapeutic eradication, no significant variation by sex has been reported. In sum, the small magnitude of these sex differences in H. pylori acquisition and clearance cannot fully explain the 2:1 incidence gap.
Steroid-based molecules are incorporated by H. pylori into its membrane lipids and differ in their potential effects on bacterial survival (78, 79) . Free-cholesterol, for example, is glucosylated after incorporation into H. pylori and acts to inhibit specific T cell responses (80) . In vitro, estradiol is bacteriostatic while progesterone and androstendione are bactericidal (81) . In H. Thus, sex differences in smoking patterns may contribute to the male predominance of gastric cancer incidence. However, Freedman et al. (5) found roughly similar male/female ratios for cancer incidence among smokers and nonsmokers, suggesting that the difference in smoking does not entirely explain the marked sex difference in gastric cancer risk. (98, 99) . Furthermore, tumors in males are more than twice as likely to be EBV-positive than tumors in females. Given this sex difference in incidence rates overall, the 2-fold sex difference in EBV positivity implies that the incidence of EBV-positive gastric cancer is four times higher in males than females.
About 9% of gastric cancers harbor Epstein-Barr virus (EBV) infection
Differences in diet between men and women might also be related to sex differences in gastric cancer incidence. In particular, low consumption of fresh fruits and vegetables may increase the risk of noncardia tumors (100), and some studies have suggested that women eat fruits and vegetables both more frequently and in greater quantities than men (101, 102) . Other factors that may potentially explain the higher risk of gastric cancer among males as compared to females are differences in medication and occupational exposures. publication bias. A greater potential concern regarding data completeness is that some of the published studies on HRT or tamoxifen did not specifically report incidence of gastric cancer, and many registered tamoxifen trials are still unpublished (7).
Our inability to detect significant between-study heterogeneity may be due to the insensitivity of the Q statistic and/or limited sample sizes. Furthermore, insufficient data precluded analyses for histologic and anatomic subtypes, which might have varying associations with the reviewed exposures. We were also unable to evaluate HRT formulation (unopposed estrogen versus estrogen plus progesterone compounds) and duration of therapy.
Our finding about tamoxifen primarily reflects observational studies with unmeasured confounding of treatment assignment. Nevertheless, limited data from randomized controlled trials was consistent. The analyses of both the randomized trial and the observational cohort data were hampered by inclusion of groups with zero events, which we addressed by marginal analyses. While this analytic approach has recognized limitations (103), alternative approaches such as continuity corrections also have drawbacks (104) . Furthermore, we could not account for the differences in dose and duration of tamoxifen treatment among studies. Thus, these results should be interpreted with caution.
We restricted our meta-analysis to associations with overt gastric cancer. However, given the recognized multistep process of gastric carcinogenesis (105) , it is necessary to consider how estrogens might influence earlier stages such as intestinal metaplasia and dysplasia. Direct assessment of estrogens would be additionally informative, as studies to date are almost exclusively based on surrogate measures. Furthermore, the effect of other selective estrogen receptor modulating drugs on gastric carcinogenesis could be usefully examined. 
